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Abstract
Background: Among people with diabetes, those with kid-
ney disease have exceptionally high rates of cardiovascular 
(CV) morbidity and mortality and progression of their under-
lying kidney disease. Finerenone is a novel, nonsteroidal, se-
lective mineralocorticoid receptor antagonist that has shown 
to reduce albuminuria in type 2 diabetes (T2D) patients with 
chronic kidney disease (CKD) while revealing only a low risk 
of hyperkalemia. However, the effect of finerenone on CV 
and renal outcomes has not yet been investigated in long-
term trials. Patients and Methods: The Finerenone in Reduc-
ing CV Mortality and Morbidity in Diabetic Kidney Disease 
(FIGARO-DKD) trial aims to assess the efficacy and safety of 
finerenone compared to placebo at reducing clinically im-
portant CV and renal outcomes in T2D patients with CKD. 
FIGARO-DKD is a randomized, double-blind, placebo-con-
trolled, parallel-group, event-driven trial running in 47 coun-
tries with an expected duration of approximately 6 years. FI-
GARO-DKD randomized 7,437 patients with an estimated 
glomerular filtration rate ≥25 mL/min/1.73 m2 and albumin-
uria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). 
The study has at least 90% power to detect a 20% reduction 
in the risk of the primary outcome (overall two-sided signifi-
cance level α = 0.05), the composite of time to first occur-
rence of CV death, nonfatal myocardial infarction, nonfatal 
stroke, or hospitalization for heart failure. Conclusions: FIGA-
RO-DKD will determine whether an optimally treated cohort 
of T2D patients with CKD at high risk of CV and renal events 
will experience cardiorenal benefits with the addition of fi-
FIGARO-DKD Phase 3 investigators and site list are included in the 
online supplementary files
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
Ruilope/Agarwal/Anker/Bakris/Filippatos/
Nowack/Kolkhof/Joseph/Mentenich/Pitt
Am J Nephrol 2019;50:345–356346
DOI: 10.1159/000503712
nerenone to their treatment regimen. Trial Registration: Eu-
draCT number: 2015-000950-39; ClinicalTrials.gov identifier: 
NCT02545049. © 2019 The Author(s)
Published by S. Karger AG, Basel
Background
Although rates of diabetes-related complications have 
declined substantially in the past 2 decades, the large bur-
den of disease persists because of the continued increase 
in the prevalence of diabetes [1]. The number of people 
with diabetes will rapidly increase, and it is estimated that 
by 2040 642 million people aged 20–79 years will have 
diabetes [2].
High blood glucose, blood pressure, serum cholester-
ol, and body mass index are risk factors for cardiovascular 
disease (CVD), and some of these factors also increase the 
risk of chronic kidney disease (CKD) and type 2 diabetes 
(T2D) [3].
Death related to cardiovascular (CV) causes is the 
main competing outcome to development of end-stage 
renal disease (ESRD) in patients with CKD. For patients 
with CKD stage 3 (estimated glomerular filtration rate 
[eGFR] ≤60 mL/min/1.73 m2), the risk of death, mainly 
due to CV events, is over 10 times higher than the risk of 
progressing to ESRD [4]. People with diabetes have a 
 10-year cumulative all-cause mortality of 11.5%, which is 
3.9% higher than the reference group without diabetes or 
CKD (7.7% cumulative 10-year mortality). In patients 
with CKD and diabetes, however, standardized mortality 
was 31.1%, representing an absolute risk difference from 
the reference group of 23.4%, even after adjustment for 
demographics and CV risk factors [5].
A three-fold increase in all-cause mortality and a 
 16-year loss in life expectancy were found in a recent in-
vestigation in patients with diabetes with early kidney dis-
ease. Mortality was nearly twice as high as for early kidney 
disease alone or diabetes without kidney disease, and life-
span loss was significantly higher than for any of the sin-
gle conditions (6 years of life span loss for early kidney 
disease and 10 years for people with diabetes) [6].
It can be concluded that the excess mortality among 
people with diabetes appears to be largely limited to the 
subgroup with kidney disease and can be explained by 
their high burden of CVDs [5, 7].
Considering the high mortality and morbidity in pa-
tients with CKD, primary prevention of its development 
but also efforts to hinder its progression once established 
are of utmost importance.
According to guidelines, CV risk factors should be sys-
tematically assessed at least annually for prevention and 
management of CVD in people with diabetes, and risk 
factors such as blood pressure, blood glucose, or lipid lev-
els controlled by applying lifestyle intervention and phar-
macological strategies. In addition, antiplatelet therapy 
may be considered as primary prevention in high-risk pa-
tients but is clearly recommended in patients with diabe-
tes with established CVD [8].
Additionally, recently approved glucose-lowering 
therapies have demonstrated reductions in CV event 
rates. In a recent meta-analysis of all CV outcome trials 
in patients with T2D, sodium-glucose cotransporter-2 
(SGLT2) inhibitors reduced major CV events (i.e., myo-
cardial infarction, stroke, or CV death) by 11%, with ben-
efit only seen in patients with atherosclerotic disease and 
not in those without [9]. SGLT2 inhibitors reduced the 
risk of CV death or hospitalization for heart failure by 
23%, with a similar benefit in patients with and without 
atherosclerotic CVD and with and without a history of 
heart failure. From mid-June 2019 onwards, among pa-
tients with T2D and albuminuria > 300 mg/g, SGLT2 in-
hibitors are recommended if eGFR is > 30 mL/min/1.73 m2 
to protect from both CV events and renal disease progres-
sion [8].
While consequent control of risk factors, optimiza-
tion of therapy, and changes in lifestyle have led to sig-
nificant reductions in CV events over the last years, 
event rates in patients with CKD (stage 3 and lower) are 
still high [9]. In particular, in T2D patients with CKD 
but without CVD in the medical history, new treatments 
such as SGLT2 inhibitors showed only moderate bene-
fits on major CV events [9] or were not sufficiently test-
ed in CV outcomes trials with glucagon-like peptide 1 
(GLP-1) analogs such as liraglutide or semaglutide [10–
12].
Plasma aldosterone concentrations and mineralocor-
ticoid receptor (MR) overactivation are associated with 
an enhanced risk of CV injury by exerting deleterious ef-
fects on the heart, kidney, brain, and peripheral vascula-
ture in preclinical investigations [13–16]. MR antagonists 
(MRAs) are evidence-based therapy in symptomatic pa-
tients with heart failure and reduced ejection fraction 
(HFrEF) [17]. Subgroup analyses of previous studies with 
the 2 steroidal MRAs spironolactone and eplerenone 
showed that MR antagonism decreases the risk of CV 
events and sudden death in patients with HFrEF and im-
paired kidney function [18–22]. Because of this evidence, 
similar morbidity and mortality benefits might also ac-
crue in T2D patients with CKD [23].
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Spironolactone is not only a direct MRA but also a 
pharmacologically active prodrug generating active me-
tabolites, such as 7 alpha-thiomethyl-spironolactone and 
canrenone, which have long half-lives and contribute to 
important side effects such as gynecomastia and hyperka-
lemia. Depending on the dose, up to 52% of male patients 
treated with spironolactone develop gynecomastia due to 
its nonspecific interaction with the homologous andro-
gen receptor, further limiting the use of this drug [24, 25]. 
Eplerenone represents the second generation of steroidal 
MRAs that does not cause gynecomastia and should be 
used with precaution in those with T2D and microalbu-
minuria because of the risk of developing hyperkalemia 
[26]. Therefore, the widespread clinical use of MRAs is 
limited by the fear and risk of developing hyperkalemia 
[27], and, if initiated, MRAs are often discontinued with-
in the first several months due to hyperkalemia [28]. For 
this reason, there is a lack of data on renal and CV out-
comes on available steroidal MRAs, eplerenone, and spi-
ronolactone, in T2D patients with CKD [29].
Finerenone is a novel nonsteroidal, selective MRA 
that has greater MR selectivity than spironolactone and 
better MR affinity than eplerenone in vitro [30, 31]. 
Furthermore, unlike spironolactone and eplerenone, 
which reach higher concentrations in renal tissue in 
comparison to cardiac tissue [32], finerenone is distrib-
uted relatively equally between the heart and the kid-
neys, at least in rodents [33]. Last, its nonsteroidal 
structure allows it to bind to the MR with high affinity 
and to inhibit recruitment of transcriptional coactiva-
tors involved in the expression of hypertrophic and 
profibrotic genes more effectively in comparison to the 
steroidal MRAs [34, 35].
In a trial involving T2D patients with the clinical diag-
nosis of CKD (MRA Tolerability Study-Diabetic Ne-
phropathy), finerenone compared to placebo showed 
only small mean changes in serum potassium and a low 
incidence of hyperkalemia, leading to a low number of 
discontinuations with no evidence of a dose-response re-
lationship. Furthermore, finerenone compared to place-
bo demonstrated a statistically significant reduction in 
urinary albumin-to-creatinine ratio (UACR) at doses 
starting from 7.5 mg onwards on top of standard of care, 
including an angiotensin-converting enzyme inhibitor 
(ACEI) or angiotensin receptor blocker (ARB) after 
90 days of treatment [36].
These findings provided the rationale for initiating a 
large-scale phase III program with finerenone investi-
gating CV and renal outcomes in T2D patients with all 
stages of CKD in 2 large-scale outcome trials. In this 
paper, we describe the design of Finerenone in Reduc-
ing CV Mortality and Morbidity in Diabetic Kidney 
Disease (FIGARO-DKD; ClinicalTrials.gov identifier 
NCT02545049) and present the baseline characteristics 
of patients enrolled into this trial. The design and base-
line characteristics of the Finerenone in Reducing Kid-
ney Failure and Disease Progression in diabetic kidney 
disease (FIDELIO-DKD, ClinicalTrials.gov identifier: 
NCT02540993) renal outcome trial are also in this issue 
of Am J Nephrol.
Patients and Methods
General Description
FIGARO-DKD is an international, multicenter, randomized, 
double-blind, placebo-controlled, parallel-group, event-driven 
study formally designed to assess whether finerenone reduces car-
diorenal morbidity and mortality in T2D patients with CKD when 
used in addition to standard of care.
Study Population
The inclusion and exclusion criteria are summarized in Table 
1. Patients included in the trial were aged ≥18 years with T2D and 
the clinical diagnosis of CKD, pretreated with ACEIs or ARBs for 
at least 4 weeks prior to the run-in visit, and had serum potassium 
≤4.8 mEq/L at both the run-in and screening visits. Patients had 
to have persistent high albuminuria (defined as UACR ≥30 mg/g 
but < 300 mg/g) and eGFR ≥25 but ≤90 mL/min/1.73 m2, or per-
sistent very high albuminuria (defined as UACR ≥300 mg/g) and 
an eGFR ≥60 mL/min/1.73 m2.
Two recruitment caps, both affecting patients with high albu-
minuria at screening, were prespecified and closed per region. The 
first cap limited the randomization of patients with eGFR ≥60 mL/
min/1.73 m2 in the medical history to approximately 10% of all 
patients randomized with high albuminuria at screening, and the 
second cap limited the randomization of patients without a his-
tory of CVD to approximately 40% of all patients randomized with 
high albuminuria at screening.
Study Design
The study design of FIGARO-DKD is illustrated in Figure 1. 
After signing the informed consent form, a run-in visit was per-
formed. If the patient met all inclusion criteria and none of the 
exclusion criteria, a mandatory run-in period that could last be-
tween a minimum of 4 and a maximum of 16 weeks started. At the 
end of the run-in period, a screening visit to confirm the patient’s 
eligibility again took place with subsequent randomization within 
2 weeks.
To account for the high variability of UACR and eGFR, patients 
were permitted to switch after either the run-in or the screening 
visit between FIGARO-DKD and the second study of the program, 
FIDELIO-DKD (ClinicalTrials.gov identifier: NCT02540993), be-
fore being randomized. As CKD in T2D is a disease continuum 
and variations in eGFR and UACR within the boundaries of this 
disease continuum do not affect the clinical risk, the switching of 
patients prior to randomization was deemed justified and neces-
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Table 1. Inclusion and exclusion criteria
Inclusion criteria Written, informed consent signed before any study-specific procedure
Men or women aged 18 years and older
Women of childbearing potential with a negative pregnancy test and agreeing to use adequate contraception
Patients with type 2 diabetes mellitus as defined by the American Diabetes Association
Patients with a clinical diagnosis of DKD based on either of the following criteria at the run-in and screening visits:
–  Persistent high albuminuria defined as UACR ≥30 mg/g (≥3.4 mg/mmol) but <300 mg/g (<33.9 mg/mmol) and eGFR ≥25 
but ≥90 mL/min/1.73 m2 (CKD-EPI) in the medical history
or
– Persistent very high albuminuria defined as UACR ≥300 mg/g (≥33.9 mg/mmol) and eGFR ≥60 mL/min/1.73 m2 (CKD-EPI)
Prior treatment with ACEIs and ARBs
Serum potassium ≤4.8 mEq/L at both the run-in and screening visits
Exclusion criteria
Medical and surgical history Known significant nondiabetic renal disease, including clinically relevant renal artery stenosis
UACR >5,000 mg/g (>565 mg/mmol) at the run-in or screening visit
Glycosylated hemoglobin >12% (>108 mmol/mol) at the run-in or screening visit
Uncontrolled arterial hypertension with mean sitting SBP ≥170 mm Hg or mean sitting DBP ≥110 mm Hg at the run-in visit or 
mean sitting SBP ≥160 mm Hg or mean sitting DBP ≥100 mm Hg at the screening visit
SBP <90 mm Hg at the run-in or screening visit
Patients with a clinical diagnosis of chronic heart failure with reduced ejection fraction and persistent symptoms (New York 
Heart Association classes II–IV) at the run-in visit
Stroke, transient ischemic cerebral attack, acute coronary syndrome, or hospitalization for worsening heart failure, in the last 
30 days prior to the screening visit
Dialysis for acute renal failure within 12 weeks prior to the run-in visit
Renal allograft in place or a scheduled kidney transplant within the next 12 months from the run-in visit
Known hypersensitivity to the study treatment (active substance or excipients)
Addison’s disease
Hepatic insufficiency classified as Child-Pugh C
Medication and drug use Concomitant therapy with eplerenone, spironolactone, any renin inhibitor, or potassium-sparing diuretic which cannot be 
discontinued at least 4 weeks prior to the screening visit
Concomitant therapy with both ACEIs and ARBs that cannot be discontinued for the purpose of the studies
Concomitant therapy with potent cytochrome P450 isoenzyme 3A4 inhibitors or inducers (to be stopped at least 7 days before 
randomization)
Other Any other condition or therapy that would make the patient unsuitable for the studies and will not allow participation for the 
full planned study period (e.g., active malignancy or other condition limiting life expectancy to <12 months)
Pregnant or breast-feeding or intention to become pregnant during the studies
Previous assignment to treatment during this studies
Previous (within 30 days prior to randomization) or concomitant participation in another clinical study (i.e., Phase I–III
clinical studies) with investigational medicinal product(s), except for participation in the run-in and screening periods of
Studies 17,530/16,244
Close affiliation with the investigational site; for example, a close relative of the investigator, dependent person (e.g., employee 
or student of the investigational site)
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; DBP, 
diastolic blood pressure; DKD, diabetic kidney disease; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; UACR, urinary albumin-to-
creatinine ratio.
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sary to reduce the burden on candidate study participants (run-in 
and screening assessments were not repeated after switching). A 
switchover from either trial was permitted only once.
Due to the anticipated recruitment period of > 2 years and the 
progressive nature of the underlying disease, rescreening was per-
mitted once. Conditions for rescreening were amended in 2017 to 
shorten the rescreening period from 6 to 3 months and allow re-
screening even if the reason for initial screen failure was an ele-
vated blood potassium value (serum potassium > 4.8 mEq/L).
Eligible patients were randomized 1: 1 via an interactive tele-
phone/web-based system to receive once-daily treatment with ei-
ther finerenone or placebo. Treatment assignment was determined 
by computer-generated random sequence with stratification by 
 region (North America, Latin America, Europe, Asia, Other), 
eGFR category at screening (25 to < 45, 45 to < 60, and ≥60 mL/
min/1.73 m2), category of albuminuria at screening (high or very 
high albuminuria), and history of CVD (present or absent). The 
definition of CVD for stratification purposes can be found in on-
line supplementary Table 1 (for all online suppl. material, see 
www.karger.com/doi/10.1159/000503712).
The starting dose of study drug was selected based on the eGFR 
measured at the screening visit: patients started on finerenone 
10  mg/day or matching placebo if eGFR was 25 to < 60 mL/
min/1.73 m2; if eGFR was ≥60 mL/min/1.73 m2, the starting dose 
was 20 mg/day. Uptitration of study drug to 20 mg/day was per-
mitted at any time after Visit 2 (Month 1); downtitration to 10 mg/
day at any time after start of treatment. Study participants were 
instructed to take the study drug tablet orally, once daily at ap-
proximately the same time every day.
Central laboratory values, including serum potassium and serum 
creatinine, are obtained at all study visits and used for confirmation 
of patients’ eligibility, safety monitoring, renal endpoint reporting, 
and end-of-study statistical analysis. From Visit 1 onwards, blood 
potassium and serum creatinine are measured at all on-treatment 
visits at a local laboratory. The investigators are instructed to use 
these local values for dose titrations and safety monitoring. Patients’ 
safety is monitored also with physical examinations (including mea-
surements of weight and vital signs) and 12-lead electrocardiograms 
at regular intervals throughout the study. Patients are assessed for 
adverse events and study endpoints at each visit and are requested to 
complete health-related quality-of-life questionnaires (EQ-5D-5L 
and Kidney Disease Quality of Life) at baseline and yearly thereafter.
The study protocol was approved by International Review 
Boards, independent ethics committees, and competent authori-
ties according to national and international regulations. FIGARO-
DKD is conducted in accordance with the ICH Harmonised Tri-
partite Guideline for Good Clinical Practice. All participants pro-
vided written, informed consent prior to entering the study.
Objectives and Endpoints
The primary endpoint of FIGARO-DKD is a composite of time 
to first occurrence of CV mortality and morbidity, as measured by 
the composite endpoint of time to first occurrence of CV death, 
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Fig. 1. Study design of FIGARO-DKD trial. a Scheduled visits will 
continue even if the study drug treatment is discontinued; b end-
of-study visit will take place only after the sponsor has officially 
terminated the study; c for all patients who have received the study 
drug. ACEI, angiotensin-converting enzyme inhibitor; ARB, an-
giotensin receptor blocker; eGFR, estimated glomerular filtration 
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The main prespecified secondary endpoint is a composite of 
time to first occurrence of kidney failure, a sustained decrease of 
eGFR ≥40% from baseline over at least 4 weeks, or renal death.
The component kidney failure of this secondary endpoint is 
defined as the occurrence of either ESRD or eGFR < 15 mL/
min/1.73 m2, confirmed by a second measurement at the earliest 
4 weeks after the initial measurement. ESRD is defined as the ini-
tiation of chronic dialysis (hemo- or peritoneal dialysis) for at least 
90 days or renal transplantation. The eGFR threshold of 15 mL/
min/1.73 m2 is consistent with the definition of kidney failure from 
Kidney Disease: Improving Global Outcomes [37] and was chosen 
in order to include an objective component to the endpoint be-
cause the decision to initiate dialysis therapy or kidney transplan-
tation may be affected by factors other than eGFR.
Other secondary endpoints include time to all-cause hospital-
ization, time to all-cause mortality, change in UACR from baseline 
to 4 months, and a composite endpoint of time to first occurrence 
of kidney failure or sustained decrease in eGFR ≥57% from base-
line over at least 4 weeks or renal death.
Statistical Considerations
Statistical Analyses
The primary efficacy endpoint for the statistical analysis is the 
time to first occurrence of the composite endpoint of CV death and 
nonfatal CV event, the latter of which consists of myocardial in-
farction, stroke, or hospitalization for heart failure. Events includ-
ed in the primary analysis will be counted from the day of random-
ization onwards until the planned end-of-study visit following the 
study sponsor’s decision to terminate the study. Patients without 
a primary efficacy endpoint event will be censored at the date of 
their last contact up to and including the end-of-study visit or their 
date of non-CV death.
In order to test for superiority of finerenone over placebo in 
prolonging the time to the first primary efficacy endpoint event, 
the null hypothesis of equal hazards in the 2 treatment groups will 
be evaluated via a log-rank test, stratified by the stratification fac-
tors region, eGFR category at screening, category of albuminuria 
at screening, and history of CVD. The treatment effect will be ex-
pressed as a hazard ratio with a corresponding confidence interval 
from a stratified Cox regression model. The statistical analyses will 
follow the intention-to-treat principle and will be based primarily 
on the full analysis set consisting of all randomized patients con-
sidered valid for analysis. An analysis on the per protocol set, ex-
cluding patients with relevant deviations from the protocol, will be 
conducted as a sensitivity analysis in which only events occurring 
within 30 days after treatment discontinuation will be considered.
In order to control the multiplicity arising from multiple tests, 
a hierarchical testing procedure will be used for the primary effi-
cacy endpoint followed by the secondary efficacy endpoints as in 
the order given above. Within the hierarchy of the primary and 
secondary efficacy endpoints, the full alpha level of 5% is forward-
ed to the next null hypothesis as long as the previous null hypoth-
esis is rejected, otherwise confirmatory testing stops at this point. 
As described under Powering and Sample Size, the actual signifi-
cance levels used at the final analysis will be slightly adjusted based 
on the formal interim analysis. The testing strategy is further illus-
trated in Figure 2. In order to declare the study successful, it will 
be considered sufficient to reject the null hypothesis related to the 
primary CV composite endpoint.
Powering and Sample Size
As an event-driven study, FIGARO-DKD has a power of 90% 
to detect a 20% relative risk reduction of finerenone versus pla-
cebo in the primary efficacy endpoint (equaling a hazard ratio 
of 0.8) based on a total of between 970 and 976 primary CV 
events and using the log-rank test at a two-sided significance 
level of α = 5.0%. Further assumptions at the planning stage in-
cluded an annual placebo event rate of 8% (assumed to be unaf-
fected by treatment discontinuations), a common annual lost-
to-follow-up rate of 0.7% in both treatment groups, an annual 
finerenone discontinuation rate of 5%, and a total treatment du-
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Fig. 2. Statistical testing strategy of primary 
and secondary efficacy endpoints for FI-
GARO-DKD. CV, cardiovascular; UACR, 
urinary albumin-to-creatinine ratio.
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period of 33 and 41 months with an equal recruitment pattern 
during the accrual period and a maximum treatment period of 
the last recruited patient of 11 and 7 months, respectively. Tak-
ing the ramp-up time during recruitment into consideration, 
this leads to an estimated required number of approximately 
6,400 patients to be randomized. Assuming a screening failure 
rate of 50%, this results in 12,800 patients to be screened. To ac-
count for the lower than assumed event rates for the primary 
endpoint as observed during the conduct of the trial, the origi-
nally planned number of randomized patients was increased by 
approximately 1,000 patients.
One formal interim analysis is planned to be conducted when 
651 primary efficacy endpoint events (i.e., 2/3 of the finally in-
tended number) have been observed. To guide the decision regard-
ing early stopping of the study for success at the interim analysis, 
the Haybittle-Peto rule will be used, requiring a two-sided p value 
below 0.00270 for both the null hypotheses corresponding to the 
primary efficacy and the key secondary renal composite endpoint 
to be rejected and leading to a minimal alpha adjustment for the 
respective tests at the final analysis stage. Additionally, for lack of 
efficacy, a nonbinding futility approach will be utilized to allow 
stopping the study at the interim analysis stage if the conditional 
power of rejecting the null hypothesis related to the primary end-
point at the final stage given the interim data fall to an unaccept-
ably low level of 10% or less.
Additional Statistical Considerations
For analysis, Austria, Belgium, Switzerland, Denmark, Germany, 
France, Italy, Netherlands, Portugal, Spain, Sweden, Great Britain, 
Finland, Norway, and Ireland are considered as countries in Western 
Europe; Bulgaria, Czech Republic, Greece, Hungary, Lithuania, 
 Poland, Ukraine, Turkey, Russia, Romania, and Slovakia as coun-
tries in Eastern Europe.
Results
Recruitment of patients for FIGARO-DKD began in 
September 2015 and was completed in October 2018. A 
total of 19,380 individuals, including 796 patients who 
were rescreened, were enrolled at 1,058 sites in 47 coun-
tries, resulting in 7,437 randomized patients. During the 
run-in or screening phase but before randomization, 
1,552 patients switched over from FIDELIO-DKD. The 
screening failure rate in all patients enrolled was 61.6 and 
18.1% in patients who switched. Eighty-three patients in 
FIGARO-DKD were excluded from the full analysis set 
due to substantial Good Clinical Practice violations, re-
sulting in 7,354 (98.9%) patients in whom the primary 
analysis will be performed.
More than 45% of patients were recruited in Europe, 
with slightly more patients being randomized in  Eastern 
Europe compared to Western Europe, 15.1% in North 
America, 22.1% in Asia, and 3.7% in Australia, New 
Zealand, and South Africa (region “Other”).
The overall trial population is predominately male 
(69.4%) and white (73.5%), with a mean age of 64.1 years 
and a mean duration of diabetes of 14.5 years. At baseline, 
mean glycosylated hemoglobin was 7.7%, mean eGFR 
67.8 mL/min/1.73 m2, mean serum potassium 4.3 mEq/L, 
and median UACR 312 mg/g. More than 60% of patients 
had an eGFR ≥60 mL/min/1.73 m2 and the proportion of 
patients with high or very high albuminuria at baseline 
was balanced.
At baseline, 4,198 patients (57.1%) were taking ARBs 
and 3,130 (42.6%) ACEIs, as requested by the protocol, 
and almost all patients (97.6%) were on glucose-lowering 
medications. More than half of the patients (54.1%) were 
using insulin, while metformin was the most frequently 
used glucose-lowering oral drug at baseline. The use of 
GLP-1 and SGLT2 inhibitors at baseline was low (7.5 and 
8.3%, respectively).
At baseline, nearly all patients (95.8%) had arterial hy-
pertension as concomitant disease and 30.8% diabetic 
retinopathy. Less than half (44.3%) had CVD in the med-
ical history: 30.9% had coronary artery disease, 17.0% 
myocardial infarction, 11.1% ischemic stroke, 15.9% pe-
ripheral artery disease, and 1.3% had a carotid endarter-
ectomy. Only 7.6% of all patients suffered from heart fail-
ure at baseline, which is related to the protocol-requested 
exclusion of all patients with HFrEF and New York Heart 
Association classes II–IV at run-in and screening. Fur-
ther information about the baseline characteristics can be 
found in Table 2 and online supplementary Table 2.
Discussion
Treatment of CVD in T2D has evolved over the last 
few decades, resulting in a substantial decline in diabetes-
related CV complications [1]. On top of improvements in 
clinical care, the health system and promotion in general 
as well as behavioral changes, newer treatments such as 
GLP-1 agonists or SGLT2 inhibitors have also demon-
strated a further reduction of CV events in people with 
T2D [10, 12, 38–41]. Despite this promising progress, 
T2D patients with CKD still exhibit residual cardiorenal 
morbidity and mortality.
The effects of canagliflozin on CV outcomes were in-
vestigated in the Canagliflozin CV Assessment Study, 
where a 14% risk reduction for death from CV causes 
nonfatal myocardial infarction, or nonfatal stroke was 
observed [37]. In the Canagliflozin and Renal Events in 
Diabetes with Established Nephropathy Clinical Evalua-
tion study investigating canagliflozin in patients with 
Ruilope/Agarwal/Anker/Bakris/Filippatos/
Nowack/Kolkhof/Joseph/Mentenich/Pitt
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T2D and CKD with very high albuminuria, a 20% risk 
reduction was observed for the same endpoint. In both 
studies, fewer effects of canagliflozin were seen in patients 
with an eGFR ≥60 mL/min/1.73 m2 or UACR ≤1,000 mg/g 
at baseline [39, 42]. In high-risk patients with an eGFR 
<45 mL/min/1.73 m2 and UACR > 1,000 mg/g at baseline, 
the event rate per 1,000 patient-years was still high with 
46.4 and 46.1 patients with an event despite treatment 
with canagliflozin, respectively. In a meta-analysis by Zel-
niker et al. [9], the effect of SGLT2 inhibitors on major 
adverse CV events (i.e., myocardial infarction, stroke, or 
CV death) was also less pronounced in patients with an 
eGFR ≥60 mL/min/1.73 m2 when compared to patients 
with an eGFR < 60 mL/min/1.73 m2.
Inflammation and fibrosis as well as oxidative stress 
mediated by MR overactivation have been well described 
in multiple organs and tissues, including the heart, ves-
sels, and kidneys [43, 44], which contrasts to the renal-
selective SGLT2 expression in the early proximal tubule 
[45].
The currently available steroidal MRAs, spironolac-
tone and eplerenone, have been investigated in clinical 
studies that varied between 4 and 52 weeks in duration 
and assessed the effects on albuminuria in different CKD 
populations. However, the effects of these MRAs on ma-
jor CV outcomes in patients with CKD are unknown 
[46]. In a recent meta-analysis, Yang et al. [47] concluded 
that treatment with spironolactone in patients with mod-
Total (n = 7,354)
Age, years, mean (SD) 64.1 (9.8)








Western Europe 1,485 (20.2)
Eastern Europe 2,019 (27.5)
North America 1,109 (15.1)
Latin America 841 (11.4)
Asia Pacific 1,625 (22.1)
Other 275 (3.7)
BMI, kg/m2, mean (SD) 31.4 (6.0)
Duration of diabetes, years, mean (SD) 14.5 (8.5)
SBP, mm Hg, mean (SD) 136 (14)
Diastolic blood pressure, mm Hg, mean (SD) 77 (10)
Heart rate, beats/min, mean (SD) 74 (11)
eGFR (CKD-EPI), mL/min/1.73 m2, mean (SD) 67.8 (21.7)
eGFR (CKD-EPI),  mL/min/1.73 m2, n (%)
≥60 4,540 (61.7)
45 to <60 1,535 (20.9)
25 to <45 1,251 (17.0)
<25 27 (0.4)
UACR, mg/g, median (25th–75th percentile) 312 (110–744)
UACR category, mg/g, n (%)
<30 198 (2.7)
30 to <300 3,385 (46.0)
≥300 3,762 (51.2)
Serum potassium, mmol/L, mean (SD) 4.3 (0.4)
HbA1c, %, mean (SD) 7.7 (1.4)
ACEIs, n (%) 3,130 (42.6)
ARBs, n (%) 4,198 (57.1)
Total (n = 7,354)
Beta-blockers, n (%) 3,524 (47.9)
Diuretics, n (%) 3,486 (47.4)
Loop diuretics 1,172 (15.9)
Thiazide diuretics 1,802 (24.5)
Calcium antagonists, n (%) 3,756 (51.1)
Statins, n (%) 5,172 (70.3)
Platelet aggregation inhibitors, n (%) 4,063 (55.2)





DPP-4 inhibitors 1,748 (23.8)
GLP-1 agonists 548 (7.5)
SGLT2 inhibitors 613 (8.3)
Arterial hypertension, n (%) 7,046 (95.8)
Diabetic retinopathy, n (%) 2,265 (30.8)
Diabetic neuropathy, n (%) 1,992 (27.1)
Lipid metabolism disorders, n (%) 3,036 (41.3)
History of cardiovascular disease, n (%) 3,260 (44.3)
Coronary artery disease 2,273 (30.9)
Myocardial infarction 1,251 (17.0)
Ischemic stroke 819 (11.1)
Peripheral arterial disease 1,168 (15.9)
Carotid endarterectomy 94 (1.3)
Heart failure, n (%) 556 (7.6)
a American Indian/Alaska Native, Native Hawaiian/other Pa-
cific Islander or multiple entries.
ACEI, angiotensin-converting enzyme inhibitor; ARB; angio-
tensin receptor blocker; BMI, body mass index; CKD-EPI, chron-
ic kidney disease epidemiology collaboration; DPP-4, dipeptidyl 
peptidase-4; eGFR, estimated glomerular filtration rate; GLP-1, 
glucagon-like peptide 1; HbA1c, glycosylated hemoglobin; SGLT2, 
sodium-glucose cotransporter-2; UACR, urine albumin-to-creat-
inine ratio; SBP, systolic blood pressure.
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erate to severe (stage 3–4) CKD was not associated with 
a significant risk reduction in major adverse CV out-
comes, hospitalization for heart failure, or all-cause or 
CV mortality compared to nonusers of spironolactone. 
They concluded, in addition, that the observed renopro-
tective benefits of spironolactone (relative risk reduction 
in ESRD by 34%) may be offset by the hyperkalemia risk 
and recommended strategic treatments to prevent hyper-
kalemia.
Finerenone is a novel, nonsteroidal, selective MRA 
that is associated with less hyperkalemia compared to ste-
roidal MRAs [48]. In the Antagonist Tolerability Study-
Diabetic Nephropathy study, finerenone induced a dose-
dependent reduction of UACR, with the largest placebo-
corrected reduction (–38%) in the group being treated 
with 20 mg once daily. Finerenone dosages over 90 days 
of treatment resulted in small declines in eGFR (~2 to 
4 mL/min/1.73 m2) and blood pressure (3–5 mm Hg) as 
well as small changes in serum potassium (+0.2 mEq/L) 
[36].
Due to its mode of action, beneficial cardiorenal ef-
fects – including CV risk reduction and delaying CKD 
progression – could result either as a direct consequence 
of the antifibrotic and anti-inflammatory efficacy of fi-
nerenone in cardiac and renal tissues or as an indirect 
consequence of improving cross-function of both end or-
gans.
The combination of FIGARO-DKD and FIDELIO-
DKD comprises the largest cardiorenal outcome pro-
gram recruited to specifically investigate the occurrence 
of fatal and nonfatal CV events and progression of kid-
ney disease in > 13,000 CKD patients with T2D. Unlike 
previous outcome trials where the levels of albuminuria 
and kidney function were advanced into stages 3 and 4, 
FIGARO-DKD has also included a cohort of patients 
with lower levels of albuminuria (high albuminuria de-
fined as UACR ≥30 mg/g but < 300 mg/g) and stage 2 
CKD (eGFR 60–90 mL/min/1.73 m2) but also patients 
with high levels of albuminuria (UACR ≥300 mg/g) and 
stage 1 and 2 CKD (eGFR ≥60 mL/min/1.73 m2), a pa-
tient population at high risk of CV events. Complement-
ed by the results of FIDELIO-DKD, the program will al-
low the evaluation of effects of finerenone in the broad-
est spectrum of CKD patients with T2D ever investigated. 
The results of FIGARO-DKD will determine whether 
an optimally treated cohort of T2D patients with CKD at 
high risk of CV events and progression of their renal dis-
ease will experience cardiorenal benefits with the addi-
tion of finerenone to their treatment regimen. Results are 
expected in 2021.
Acknowledgments
The authors express their sincere appreciation to all involved 
colleagues in the study centers for their participation in this trial. 
The authors would also like to acknowledge all the patients who 
are participating in this trial. The authors thank the study coordi-
nators Michelle King, Laurence West, Angela May (all Bayer PLC, 
Reading, UK), Stefania Collamati (Bayer SpA, Milan, Italy), Lydia 
Christopher (SLS Services employee performing services for Bayer 
PLC, Reading, UK), Anna Lindroth (Bayer AB, Solna, Sweden), 
Cecilia Fedorov (PRA Health Sciences employee performing ser-
vices for Bayer Inc., Mississauga, Canada), GoUne You (Bayer 
 Korea Ltd., Seoul, South Korea), Dirk Alta (Bayer B.V., Mijdrecht, 
Netherlands), the data managers Jeannette Gerstner, Jacobus 
 Buytendach (Bayer AG, Berlin, Germany), Martin Gregory (PRA 
Health Sciences employee performing services for Bayer AG, 
 Berlin, Germany), and the Statistical Analysts Cosima Klein, Aziz 
Tuemer, and Dominik Habel (all Bayer AG, Berlin, Germany). 
Special thanks to Meike Brinker (Bayer AG, Wuppertal, Germany) 
for her continuous support of the program in different important 
roles.
Statement of Ethics
The study protocol was approved by international review 
boards, independent Ethics Committees, and competent authori-
ties according to national and international regulations. FIGARO-
DKD is conducted in accordance with the ICH Harmonised Tri-
partite Guideline for Good Clinical Practice. All participants pro-
vided written, informed consent before entering the study.
Disclosure Statement
L.M.R. has served as an advisor/speaker for AstraZeneca, Bay-
er, Daiichi-Sankyo, Medtronic, Novartis, and Recordati. R.A. is a 
member of data safety monitoring committees for AstraZeneca 
and Ironwood Pharmaceuticals; a member of steering committees 
of randomized trials for Akebia, Bayer, Janssen, GlaxoSmithKline, 
Relypsa, and Sanofi and Genzyme US Companies; a member of 
adjudication committees for Bayer, Boehringer Ingelheim, and 
Janssen; and a member of a scientific advisory board or a consul-
tant for Bird Rock Bio, Celgene, Daiichi Sankyo, Inc., Eli Lilly, Re-
lypsa, Reata, Takeda Pharmaceuticals, USA, and ZS Pharma; he 
has served as associate editor of the American Journal of Nephrol-
ogy and Nephrology Dialysis and Transplantation and has been an 
author for UpToDate; and he has received research grants from the 
U.S. Veterans Administration and the National Institutes of 
Health. S.D.A. has received research support from Abbott Vascu-
lar and Vifor International, and personal fees from Boehringer In-
gelheim, Bayer, AstraZeneca, Novartis, Vifor International, Im-
pulse Dynamics, Respicardia, and St. Jude Medical. G.L.B. reports 
research funding, paid to the University of Chicago, from Bayer, 
Janssen, and Vascular Dynamics; he has acted as a consultant for 
Merck, Vascular Dynamics, Relypsa, Boehringer Ingelheim, Sano-
fi, Pfizer, Novo Nordisk, Ionis, and AstraZeneca; he is an editor of 
the American Journal of Nephrology, Nephrology and Hyperten-
sion, and section editor of UpToDate; and he is associate editor of 
Ruilope/Agarwal/Anker/Bakris/Filippatos/
Nowack/Kolkhof/Joseph/Mentenich/Pitt
Am J Nephrol 2019;50:345–356354
DOI: 10.1159/000503712
Diabetes Care and Hypertension Research. G.F. reports that he is 
a committee member of trials and registries sponsored by Bayer, 
Novartis, Servier, Vifor, Medtronic, and Boehringer Ingelheim. 
C.N., P.K., A.J., and N.M. are full-time employees of Bayer AG, 
Division Pharmaceuticals, Germany. B.P. reports consultant fees 
for Bayer, AstraZeneca, Sanofi, scPharmaceuticals, SQ Innovation, 
G3 Pharmaceuticals, Sarfez, Vifor, Cereno, Ardelyx, KBP Biosci-
ences and Windtree Pharmaceuticals; he has stock options for KBP 
Biosciences, SQ Innovation, Sarfez, scPharmaceuticals, Cereno 
and G3 Pharmaceuticals, and Relypsa; he also holds a patent for 
site-specific delivery of eplerenone to the myocardium (US patent 
#9931412).
Funding Sources
FIGARO-DKD is a research study conducted and funded by 
Bayer AG.
Author Contributions
The sponsor designed the study in conjunction with the Execu-
tive Committee. L.M.R. wrote the first draft of the paper, had full 
access to the study design information, and had final responsibil-
ity for the decision to submit for publication. All authors provided 
input for the preparation of subsequent drafts and approved the 
final version for submission. Technical editorial assistance was 
provided by Lynda Chang, PhD, of McCann Health, and was fund-
ed by Bayer AG. All authors reviewed and approved the manu-
script.
Appendix
Program Management and Committees
FIGARO-DKD is a research study conducted and funded by 
Bayer AG. The study protocol was written by the sponsor in close 
collaboration with the members of the Executive Committee (EC).
The EC supervises the conduct of the program, supported the 
protocol development, and provides ongoing scientific guidance. 
The members of the EC are L.M.R., G.L.B., G.F., and B.P., as well 
as R.A. (Chairman of the Renal Clinical Event Committee) and 
S.D.A. (Chairman of the CV Clinical Event Committee). A steer-
ing committee including the EC members, worldwide country lead 
investigators, and additional content experts is responsible for sci-
entific guidance and local implementation of the protocols. The 
authors are responsible for drafting and editing this design and 
baseline paper and its content.
Data Monitoring Committee
Periodic assessments of safety and efficacy are performed in 
FIGARO-DKD by an independent Data Monitoring Committee, 
which also oversees the safety and efficacy in FIDELIO-DKD. One 
interim analysis for overwhelming efficacy in terms of reducing 
the primary CV efficacy endpoint as well as the main secondary 
renal endpoint was prespecified to occur after accrual of 67% of the 
planned primary CV efficacy endpoints. Members of the indepen-
dent Data Monitoring Committee are Murray Epstein (Chair), 
Aldo P. Maggioni (Chair), Glenn M. Chertow, Gerald DiBona, 
Jean Rouleau, Jose Lopez-Sendon, and Tim Friede (Statistician).
Central Clinical Event Committee
All potential outcome events are independently reviewed and 
adjudicated by a Clinical Event Committee, which consists of 3 
subcommittees (cardiac, renal, and neuro). All potential outcome 
events are randomly distributed to 2 members of the appropriate 
subcommittee. If there is disagreement between the 2 initial re-
viewers, the event will be distributed to a third reviewer. If the third 
reviewer does not agree with either of the first 2 reviewers, the 
event will be reviewed at a panel meeting in order to reach a deci-
sion.
Members of the Renal Clinical Event Committee are R.A. 
(Chair), Pantelis Sarafidis, Alan Jardine, Phyllis August, Sankar 
Navaneethan, and Titte Srinivas; members of the Cardiac Clinical 
Event Committee are S.D.A. (Chair), Andrew Coats, Piotr Poni-
kowski, John Teerlink, Barry Greenberg, James Januzzi, Stephan 
von Haehling, and Wolfram Doehner; members of the Neuro 
Clinical Event Committee are Wolfram Doehner (Chair), Turgut 
Tatlisumak, Lauren Phillips, Carlos Kase, and Hans Diener.
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